Humana · Daa Pangenotypic Epclusa · US health-plan appeal rights

Daa Pangenotypic Epclusa denied due to quantity / dose limits by Humana?

Q: How long do I have to appeal a Humana Daa Pangenotypic Epclusa denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-11

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Humana typically requires

Humana's specific coverage criteria for daa pangenotypic epclusa are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Humana Drug List / Part D Formulary; Humana Medical Coverage Policy Hepatitis C

The Humana angle on Daa Pangenotypic Epclusa

## Why Humana Issued a Quantity-Limit Denial for Epclusa

Epclusa (sofosbuvir/velpatasvir) is dispensed as a fixed-dose combination taken once daily for a treatment duration specified in the FDA-approved prescribing label — the exact duration depends on the patient's genotype, cirrhosis status, and prior treatment history. Humana's quantity-limit (QL) controls are programmed to the standard treatment duration described in that label. A QL denial most commonly occurs when the quantity requested exceeds the plan's default limit — for example, when a prescriber orders an extended course for a treatment-experienced or cirrhotic patient without accompanying documentation explaining the clinical basis for the longer duration.

Quantity-limit denials are appealable. The appeal strategy is straightforward: document the clinical reason the prescribed quantity is medically necessary by linking the patient's genotype, cirrhosis status, and treatment history to the duration specified in the prescribing label and in the applicable AASLD/IDSA hepatitis C guidance.

## Federal Appeal Framework

ACA Section 2719 / external review: Non-grandfathered plans must offer independent external review after internal appeals are exhausted. The standard deadline is approximately four months from denial; verify the exact date on your Explanation of Benefits. Expedited review (roughly 72 hours) is available for urgent situations.
ERISA Section 503: Employer-sponsored plans must provide a full-and-fair review, including the written criteria used to set the quantity limit.

## Concrete Appeal Steps and Timeline

1. Obtain the denial letter and Humana's published quantity-limit criteria for hepatitis C DAAs. 2. Confirm the treatment duration specified in the FDA-approved Epclusa prescribing label for the patient's specific genotype and clinical profile. 3. File a Level 1 internal appeal within the plan-stated deadline, attaching clinical documentation supporting the prescribed quantity. 4. If upheld, escalate to external review before the window closes.

## Documentation to Gather

Diagnosis and genotype: Current genotype result, viral load, and fibrosis/cirrhosis staging establishing which label-specified treatment duration applies.
Prior-treatment history: Documentation of treatment-naive versus treatment-experienced status, which directly determines recommended duration per the prescribing label.
Prescriber attestation: A letter from the treating provider citing the FDA-approved prescribing information and professional society guidance (e.g., the applicable AASLD/IDSA recommendation) as the basis for the prescribed quantity, and documenting why a shorter course would be clinically inappropriate.
Clinical chart notes: Progress notes or consultation records supporting the prescriber's clinical reasoning.

## Criteria-Mapping Structure

From (a) the Epclusa prescribing label treatment-duration table and (b) Humana's QL policy for hepatitis C agents, list each requirement and provide the chart-based answer. If the label specifies a longer duration for the patient's specific situation, quote the relevant label language and attach it as an exhibit. This approach grounds the appeal in the FDA-approved standard rather than in a clinical opinion alone.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Humana appeals

Other denial reasons for Humana Daa Pangenotypic Epclusa

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-11. Editorial standards: denialhelp.com/authors.